Agoraphobia
Fear of places and situations that might cause panic, helplessness, or embarrassment.
Agoraphobia is an anxiety disorder that often develops after one or more panic attacks.
Symptoms include fear and avoidance of places and situations that might cause feelings of panic, entrapment, helplessness, or embarrassment.
Treatments include talk therapy and medication.
Cluster Number: F-1
Wiki Number: W003
Diagnosis: Agoraphobia
US Patients: 1.7% Adults
World Patients:
Sex Ratio: M-2W
Age Onset: 20+
Brain Area: Extra epinephrine – poor balance
Symptoms: environment unsafe-no escape
Progression: Open spaces or outside home; may lead to 10-30 minute panic attack or PTSD
Causes:
Medications: antidepressants; anti-anxiety
Therapies: relaxation, systematic desensitization, expanding exposuresCBT-50%
Youtube Video: What is Agoraphobia?
Amazon or Library Book:
The Agoraphobia Workbook
Click on the book to link or buy from Amazon.
Contact your local Social Security office for possible Disability Benefits through their Disability Determination Services,
Section 12.06.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Cost-effectiveness analysis of mindfulness-based cognitive therapy in patients with anxiety disorders in secondary mental health care settings alongside a randomized controlled trialby Mitsuhiro Sado on November 11, 2024
INTRODUCTION: Anxiety disorder is one of the most prevalent mental disorders. Mindfulness-based cognitive therapy (MBCT) is effective for treating anxiety disorders. However, no studies have investigated the cost-effectiveness of MBCT for anxiety disorders. We aimed to conduct a cost-effectiveness analysis alongside a randomized controlled trial (RCT) to clarify the cost-effectiveness of MBCT for anxiety disorders.
- Delayed onset autoimmune cholangitis in a patient treated with pembrolizumabby Joshua Newington on November 8, 2024
This case study describes a female patient in her late 70s who developed autoimmune cholangitis a year after finishing 35 cycles of pembrolizumab for the treatment of her non-small cell lung cancer. The diagnosis was initially missed and delayed; the patient's agoraphobia and the COVID-19 pandemic were noted as contributing factors.
- Corrigendum to "Personalized virtual reality exposure for panic disorder and agoraphobia: A preliminary neurophysiological study" [Comprehensive Psychiatry Volume 129 (2024) 152447]by Han Wool Jung on October 31, 2024
No abstract
- Modern day scurvy in a patient with agoraphobia: A case reportby Avneesh Bhangu on October 30, 2024
No abstract